KLK3 and neoplasm: Although current clinical and pathological measures such as Gleason score (tumor grade), disease stage, and prostate-specific antigen (PSA) level provide important prognostic information, they do not accurately predict an individual patient's risk of progression, and better markers to aid prognostication are needed [4, 5].